Skip to content
Screener

Beam Therapeutics BEAM Q1 2026 earnings

Reported May 7, 2026 · Before market open

Revenue$31.7MBeat by $20.8M
EPS-$0.91Miss by $0.04
Revenue estimate$11.0M
EPS estimate-$0.87

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$8.8M
EPS estimate-$1.16

Financials

Q1 2026

Income statement

See full
Revenue$31.7M+325%
Operating income-$107.2M+10.1%
Net income-$94.3M+12.9%
EPS (diluted)-$0.91+26.0%

Balance sheet

See full
Cash & equivalents$288.3M-45.4%
Total debt$250.8M+58.6%
Total equity$1.2B+3.1%
Total assets$1.5B+0.9%

Cash flow

See full
Operating cash flow-$128.5M-23.7%
CapEx$2.2M-27.2%
Free cash flow-$130.7M-22.2%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$2.43B+24.5%
Enterprise value$2.39B+51.2%
P/S14.8×-15.9×

Profitability

See full
Operating margin-226.6%-90.5pp
FCF margin-234%-86.6pp

Returns & leverage

See full
Debt / equity0.2×+0.1×
Current ratio17×+8.2×

FAQ

When did Beam Therapeutics report Q1 2026 earnings?
Beam Therapeutics (BEAM) reported Q1 2026 earnings on May 7, 2026 before market open.
What were Beam Therapeutics's Q1 2026 revenue and EPS?
Beam Therapeutics reported revenue of $31.7M and eps of $-0.91 for Q1 2026.
Did Beam Therapeutics beat estimates in Q1 2026?
Revenue beat the consensus estimate of $11.0M by $20.8M. EPS missed the consensus estimate of $-0.87 by $0.04.
How did Beam Therapeutics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 324.9% from $7.5M a year earlier and eps grew 26.6% from $-1.24.
Where can I find Beam Therapeutics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-210299) and the 10-Q periodic report (0001193125-26-210338) directly on SEC EDGAR. The filing index links above go to sec.gov.